Featured Research

from universities, journals, and other organizations

Cardiac Effects Associated With Breast Cancer Treatment Appear Lower With Dose-dense Chemotherapy

Date:
March 10, 2008
Source:
Memorial Sloan-Kettering Cancer Center
Summary:
Breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity, new research suggests.

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity. While previous reports evaluating the cardiac effects of breast cancer treatments including trastuzumab and anthracyclines have shown an acceptable safety margin, the new study demonstrates an even lower risk of cardiac toxicity when standard doses of these drugs are administered more frequently over time -- a treatment plan called "dose-dense," which has previously been shown to be a more effective anti-cancer approach.

The researchers used a dose-dense regimen of doxorubicin (Adriamycin®) and cyclophosphamide (Cytoxan® or Neosar®) followed by paclitaxel (Taxol®) and found that the regimen -- when given every two weeks instead of three -- pairs safely with trastuzumab, a drug that is used to treat breast cancer in women whose tumors contain the protein receptor called HER2.

According to the findings, only 1.4 percent (one patient) of the 70 early-stage breast cancer patients treated with this regimen experienced congestive heart failure after 28 months of follow-up. This rate of cardiac toxicity is lower than the 4 percent threshold that is generally considered acceptable, and still lower than what was found in larger, previously published trials evaluating conventionally scheduled treatment with the use of trastuzumab.

The study's authors concluded that this dose-dense regimen combined with trastuzumab is a safe and effective way to treat women with early-stage HER2-positive breast cancer in the adjuvant setting and there is no need to forgo the use of this regimen because trastuzumab is also being administered.

Chau Dang, MD, a medical oncologist on the Breast Cancer Medicine Service at MSKCC, led the study, and Clifford Hudis, MD, Chief of the Breast Cancer Medicine Service at MSKCC, is the paper's senior author.

The study will be published in the March 10, 2008, issue of the Journal of Clinical Oncology and was supported by grants from Genentech and Amgen.


Story Source:

The above story is based on materials provided by Memorial Sloan-Kettering Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Memorial Sloan-Kettering Cancer Center. "Cardiac Effects Associated With Breast Cancer Treatment Appear Lower With Dose-dense Chemotherapy." ScienceDaily. ScienceDaily, 10 March 2008. <www.sciencedaily.com/releases/2008/03/080310181553.htm>.
Memorial Sloan-Kettering Cancer Center. (2008, March 10). Cardiac Effects Associated With Breast Cancer Treatment Appear Lower With Dose-dense Chemotherapy. ScienceDaily. Retrieved April 19, 2014 from www.sciencedaily.com/releases/2008/03/080310181553.htm
Memorial Sloan-Kettering Cancer Center. "Cardiac Effects Associated With Breast Cancer Treatment Appear Lower With Dose-dense Chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2008/03/080310181553.htm (accessed April 19, 2014).

Share This



More Health & Medicine News

Saturday, April 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) — Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) — In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) — A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) — The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins